## **Supplemental Data**

## Rationally Designed Anti-CRISPR Nucleic Acid Inhibitors of CRISPR-Cas9

Christopher L. Barkau<sup>1</sup>, Daniel O'Reilly<sup>2</sup>, Kushal J. Rohilla<sup>1</sup>, Masad J. Damha<sup>2,\*</sup>, and Keith T. Gagnon<sup>1,3,\*</sup>


<sup>1</sup>Department of Biochemistry & Molecular Biology, School of Medicine, Southern Illinois University

<sup>2</sup>Department of Chemistry, McGill University


<sup>3</sup>Department of Chemistry & Biochemistry, Southern Illinois University

\*Corresponding authors: masad.damha@mcgill.ca, ktgagnon@siu.edu

Table S1: Sequence of RNA and DNA Oligonucleotides	nd DNA Oligonucleotides
Guide RNAs and Oligonucleotides	Guide RNAs and Oligonucleotides Sequence (lowercase = RNA. uppercase = DNA)
crE2	uaccagcaaaacacuccgauguuuuagagcuaugcuguuuug gcaaaaccaccuccgauguuuuagagcuaugcuguuuug
crEGIP	bnnnibabbenninbabbebbbbbbb
tracrRNA	aaacagcanagcaagunaaaanaaggcuaguccgunancaacungaaaaaguggcaccgagucgguna
sgEGIP	gggcgaggagcuguucaccgguuuuagagcuagaaaaaggcaaguuaaaaaaaa
T7 promoter oligo	TAATACGACTCACTATA
T7_tracrRNA_as	AAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGGACTAGCCTTATTTTAACTTGCTATGCTGTTTCCCTATAGTGAGTG
T7 sgEGIP as	AAGCACCGACTCGGTGCCACTTTTTCAAGTTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACCGGTGAACAGCTCCTCGCCCTATAGTGAGTCGTATTA
pEGIP vitro targ F	ATGCGATGGAGTTTCCCCA
pEGIP vitro targ R	CCGCTTTACTTGTACAGCTCG



<u>Figure S1.</u> Determining the active concentration of Cas9 and its binding affinity to native dual-RNA guides. (A) Cas9 enzyme stocks were titrated with a fixed concentration of tracrRNA-crRNA complex (0.5 μM). Active concentration of Cas9 was determined by solving for x when the equations of the two lines were set equal to each other, as described in Methods. (B) Binding of Cas9 to tracrRNA or Cas9-tracrRNA complex to crRNA. Binding affinities were calculated by non-linear regression and fitting to a one-site binding curve. Error bars are standard error of the mean (s.e.m.).



**Figure S2.** (**A**) Quantification of gel shift analyses comparing crRNA binding and affinity to Cas9-tracrRNA complex or tracrRNA alone. (**B-C**) Testing of different conditions for inhibitor testing in in vitro cleavage assays. Condition 1: Pre-assemble RNP complex, then mix with target and inhibitor, Condition 2: Pre-assemble RNP, incubate with inhibitor, then mix with target, Condition 3: Pre-incubate inhibitor with Cas9-tracrRNA complex, then mix with crRNA and target. (**D**) Quantification of dgRNA and sgRNA Cas9 inhibition. *IC*50 values were calculated by fitting to a variable slope dose-response inhibition curve. All error bars are standard error of the mean (s.e.m.).